Trial intelligence / Profile preview

Vaccination response study in immunosuppressed patients with rheumatic autoimmune diseases

2008-001282-28Phase 4Terminated

Sponsor
Radboud University Medical Center
Start
Aug 2008
Modality
Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 4 trial of influenza vaccine, 23-valent pneumococcal polysaccharide vaccine and Recombivax HB in influenza, pneumococcal disease and hepatitis B (HBV) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Humoral response to influenza vaccination, Humoral response to pneumococcal vaccination and 1 more. Started Aug 2008; status: terminated.

02

Drugs

influenza vaccine23-valent pneumococcal polysaccharide vaccineRecombivax HB
03

Conditions

influenzapneumococcal diseasehepatitis B (HBV)

Beyond the preview

Go deeper on 2008-001282-28.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-001282-28.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call